Skip to main content
CLYM logo
CLYM
(NASDAQ)
Climb Bio, Inc.
$6.56-- (--)
Loading... - Market loading

Climb Bio, Inc. (CLYM) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Climb Bio, Inc. stock.

Analyst Consensus Rating

Investment consensus from 10 professional research analysts

Consensus Rating

Strong Buy
Based on 10 unique analysts
(12 total ratings in last 90 days)
High Confidence:1 Buy/Sell

Average Price Target

$16.20
146.95% Upside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest CLYM Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Mayank Mamtani
B Riley
Strong BuyInitiates
$26.00
Danielle Brill
Truist
Strong BuyInitiates
$17.00
Christopher Raymond
Raymond James
Strong BuyInitiates
$25.00
Raghuram Selvaraju
HC Wainwright
Strong BuyMaintains
$11.00 $15.00
Christopher Raymond
Raymond James
BuyInitiates
$25.00
Laura Chico
Wedbush
BuyMaintains
$12.00 $14.00
Thomas Smith
Leerink Partners
BuyReiterates
$10.00
Colleen Kusy
Baird
BuyMaintains
$9.00 $12.00
Laura Chico
Wedbush
BuyInitiates
$12.00
Julian Harrison
BTIG
BuyMaintains
$8.00
Colleen M. Kusy
Baird
BuyMaintains
$9.00 $12.00
Yasmeen Rahimi
Piper Sandler
BuyInitiates
$23.00

Frequently Asked Questions

What is the analyst consensus rating for CLYM?

The analyst consensus rating for CLYM is "Strong Buy" based on 10 analyst recommendations.

What is the average price target for CLYM?

The average 12-month price target for CLYM is $16.20, representing an upside of 147.0% from the current price of $6.56.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.